Proteomics Indicates Lactate Dehydrogenase Is Prognostic in Acetaminophen-Induced Acute Liver Failure Patients and Reveals Altered Signaling Pathways
Vazquez JH, Kennon-McGill S, Byrum SD, Mackintosh SG, Jaeschke H, Williams DK, Lee WM, Dranoff JA, McGill MR, Group A. Proteomics Indicates Lactate Dehydrogenase Is Prognostic in Acetaminophen-Induced Acute Liver Failure Patients and Reveals Altered Signaling Pathways. Toxicological Sciences 2022, 187: 25-34. PMID: 35172013, PMCID: PMC9216044, DOI: 10.1093/toxsci/kfac015.Peer-Reviewed Original ResearchConceptsAcute liver failureEnd-stage liver diseaseALF patientsLactate dehydrogenaseLiver diseaseDay 1Acute Liver Failure Study GroupAcute liver failure patientsTransplant-free survivorsKing's College criteriaLiver failure patientsMost clinical laboratoriesFailure patientsLiver failurePrognostic valueControl volunteersAlanine aminotransferaseStudy groupPrognostic potentialPeak injuryDay 3Good biomarkerDay 1 samplesNonsurvivorsPatientsShort‐Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis
McGill MR, James LP, McCullough SS, Moran JH, Mathews SE, Peterson EC, Fleming DP, Tripod ME, Vazquez JH, Kennon‐McGill S, Spencer HJ, Dranoff JA. Short‐Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis. Hepatology Communications 2022, 6: 361-373. PMID: 34558847, PMCID: PMC8793989, DOI: 10.1002/hep4.1810.Peer-Reviewed Original ResearchConceptsAPAP-protein adductsAcetaminophen useCirrhosis groupClinical outcomesDay 5Sensitive biomarkerAdverse clinical outcomesShort-term administrationCompensated cirrhosisLiver injuryAPAP administrationLiver damagePK analysisCurrent guidelinesStudy initiationCirrhosisTerm safetyDay 1Day 3APAP metabolitesHigh dosesPatientsPilot studyAPAPLonger treatment